Tyrosine Kinase Inhibitors in DyplAsia of Lung Epithelium

Trial Profile

Tyrosine Kinase Inhibitors in DyplAsia of Lung Epithelium

Discontinued
Phase of Trial: Phase II

Latest Information Update: 23 Aug 2016

At a glance

  • Drugs Gefitinib (Primary)
  • Indications Head and neck cancer; Non-small cell lung cancer; Precancerous conditions
  • Focus Therapeutic Use
  • Acronyms TIDAL1
  • Most Recent Events

    • 29 Apr 2016 Planned End Date changed from 1 Dec 2016 to 1 Jun 2016.
    • 29 Apr 2016 Status changed from recruiting to discontinued.
    • 19 Oct 2015 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top